drugset / Trial / NCT01298687

Divided Dose of TRAVATAN®

NCT01298687

Phase 2 Completed 67 enrolled Alcon Research
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the incremental dosing of travoprost ophthalmic solution versus once a day dosing of TRAVATAN® in lowering intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Timeline

Start
2011-02
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Travoprost Other / unclassified 0.00013 % Other
Subject Travoprost Other / unclassified 0.00033 % Other
Subject Travoprost Other / unclassified 0.001 % Other
Subject Travoprost Other / unclassified 0.00267 % Other
Subject Travoprost Other / unclassified 0.004 % Other